[1] McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma[J]. Oral Oncol, 2008, 44(11): 1039-1046. [2] Mikkelsen LH, Larsen AC, von Buchwald C, et al. Mucosal malignant melanoma -- a clinical, oncological, pathological and genetic survey[J]. APMIS, 2016, 124(6): 475-486. [3] Nassar KW, Tan AC.The mutational landscape of mucosal melanoma[J]. Semin Cancer Biol, 2020, 61: 139-148. [4] Papaspyrou G, Garbe C, Schadendorf D, et al.Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors[J]. Melanoma Res, 2011, 21(6): 475-482. [5] Spencer KR, Mehnert JM.Mucosal melanoma: epidemiology, biology and treatment[J]. Cancer Treat Res, 2016, 167: 295-320. [6] Zhou R, Shi C, Tao W, et al.Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations[J]. Clin Cancer Res, 2019, 25(12): 3548-3560. [7] Bai X, Mao L, Guo J.Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)[J]. Chin J Cancer Res, 2019, 31(5): 740-741. [8] Bhaskar SB.Clinical trial registration: a practical perspective[J]. Indian J Anaesth, 2018, 62(1): 10-15. [9] Newell F, Kong Y, Wilmott JS, et al.Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets[J]. Nat Commun, 2019, 10(1): 3163. [10] Chi Z, Li S, Sheng X, et al.Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases[J]. BMC Cancer, 2011, 11: 85. [11] Tripp MK, Watson M, Balk SJ, et al.State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now[J]. CA Cancer J Clin, 2016, 66(6): 460-480. [12] Kim HS, Jung M, Kang HN, et al.Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition[J]. Oncogene, 2017, 36(23): 3334-3345. [13] Hayward NK, Wilmott JS, Waddell N, et al.Whole-genome landscapes of major melanoma subtypes[J]. Nature, 2017, 545(7653): 175-180. [14] Tacastacas JD, Bray J, Cohen YK, et al.Update on primary mucosal melanoma[J]. J Am Acad Dermatol, 2014, 71(2): 366-375. [15] 吴云腾, 任国欣, 孙沫逸,等. 中国头颈黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2015, 13(3): 262-269. [16] Hodi FS, Corless CL, Giobbie-Hurder A, et al.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin[J]. J Clin Oncol, 2013, 31(26): 3182-3190. [17] Si L, Guo J.C-kit-mutated melanomas: the Chinese experience[J]. Curr Opin Oncol, 2013, 25(2): 160-165. [18] D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis[J]. J Clin Oncol, 2017, 35(2): 226-235. [19] Shoushtari AN.About face: molecular aberrations in head and neck mucosal melanomas[J]. Clin Cancer Res, 2019, 25(12): 3473-3475. |